Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Baxter
Boehringer Ingelheim
Colorcon
Mallinckrodt

Last Updated: August 15, 2022

Investigational Drug Information for APD421


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug APD421?

APD421 is an investigational drug.

There have been 10 clinical trials for APD421. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Postoperative Nausea and Vomiting, Vomiting, and Nausea. The leading clinical trial sponsors are Acacia Pharma Ltd and [disabled in preview].

There is one US patent protecting this investigational drug and ten international patents.

Recent Clinical Trials for APD421
TitleSponsorPhase
Study of APD421 With and Without OndansetronAcacia Pharma LtdPhase 1
Mass-balance Study of [14C]-APD421 in Healthy VolunteersAcacia Pharma LtdPhase 1
Study of APD421 as PONV Treatment (Prior Prophylaxis)Acacia Pharma LtdPhase 3

See all APD421 clinical trials

Clinical Trial Summary for APD421

Top disease conditions for APD421
Top clinical trial sponsors for APD421

See all APD421 clinical trials

US Patents for APD421

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
APD421 See Plans and Pricing METAP2 inhibitors and methods of treating obesity SynDevRx, Inc. (Cambridge, MA) See Plans and Pricing
APD421 See Plans and Pricing Pyrimidinyl-diazospiro compounds Convergence Pharmaceuticals Limited (Maidenhead, GB) See Plans and Pricing
APD421 See Plans and Pricing Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Baxter
Boehringer Ingelheim
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.